Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
News & Analysis: Ionis Pharmaceuticals
A licensing deal gives investors confidence in a turnaround.
Ionis Pharma has some powerful numbers now. But its future opportunities are even more amazing.
The Rule of 40 is a quick and dirty way to value stocks before you add them to your portfolio.
IONS earnings call for the period ending June 30, 2019.
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
A large licensing payment from one of the biotech's partners drives revenue growth.
IONS earnings call for the period ending March 31, 2019.
Information from competitors and a collaborator sent the high-flying biotech lower.